Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings.

Tezepelumab, a biologic treatment for chronic obstructive pulmonary disease (COPD), was found to reduce the rate of COPD exacerbations in individuals with a wide range of blood eosinophil levels, according to the phase 2a COURSE trial. While the overall trial did not achieve a statistically significant reduction in exacerbations compared to placebo, tezepelumab was successful in reducing exacerbations in subgroups of participants with blood eosinophil count levels of 150 cells/¿L or greater. These findings are significant as they demonstrate the potential for tezepelumab to be effective in a broad range of COPD patients. [Extracted from the article]